J

Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015

Watchlist Manager
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Watchlist
Price: 156 SAR 4.7% Market Closed
Market Cap: 10.9B SAR
Have any thoughts about
Jamjoom Pharmaceuticals Factory Company SJSC?
Write Note

Jamjoom Pharmaceuticals Factory Company SJSC
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jamjoom Pharmaceuticals Factory Company SJSC
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
J
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Pre-Tax Income
ď·Ľ315.8m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC
SAU:2070
Pre-Tax Income
ď·Ľ71.6m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
-13%
M
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Pre-Tax Income
ď·Ľ71.4m
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jamjoom Pharmaceuticals Factory Company SJSC
Glance View

Market Cap
10.9B SAR
Industry
Pharmaceuticals

Jamjoom Pharmaceuticals Factory Company SJSC, nestled in the heart of Saudi Arabia, has emerged as a formidable player in the Middle East's pharmaceutical landscape. Founded in 1994, the company was borne out of a vision to cater to the growing healthcare demands of the region, leveraging both high-tech manufacturing and rigorous scientific research. Initially focused on generic medications, Jamjoom Pharmaceuticals has since expanded its portfolio to include a diverse range of products from ophthalmology to dermatology. With a state-of-the-art manufacturing facility in Jeddah, it integrates advanced technologies into its processes, ensuring that its products meet global quality standards. The company's adherence to Good Manufacturing Practices (GMP) and its drive to innovate are reflected in its collaborations with international partners for research and development, exemplifying its commitment to producing affordable, high-quality medications. At the core of Jamjoom Pharmaceuticals' business model is a robust distribution network that spans across the Middle East and North Africa (MENA) region, facilitating seamless supply chain operations. Revenue is generated primarily through the sale of its diversified product line, which includes prescription medications, over-the-counter solutions, and specialized healthcare products. The company leverages relationships with hospitals, healthcare providers, and retail pharmacies to enhance its market penetration. Its strategic focus on emerging therapeutic areas and persistent efforts to expand its international presence are paying dividends as it grows its footprint beyond the MENA region. By consistently reinvesting in research and development, Jamjoom Pharmaceuticals keeps its pipeline replenished with innovations that not only promise to enhance patient outcomes but also ensure sustainable profitability in a competitive pharmaceutical market.

Intrinsic Value
102.07 SAR
Overvaluation 35%
Intrinsic Value
Price
J

See Also

What is Jamjoom Pharmaceuticals Factory Company SJSC's Pre-Tax Income?
Pre-Tax Income
315.8m SAR

Based on the financial report for Dec 31, 2023, Jamjoom Pharmaceuticals Factory Company SJSC's Pre-Tax Income amounts to 315.8m SAR.

What is Jamjoom Pharmaceuticals Factory Company SJSC's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
11%

Over the last year, the Pre-Tax Income growth was 69%. The average annual Pre-Tax Income growth rates for Jamjoom Pharmaceuticals Factory Company SJSC have been 11% over the past three years .

Back to Top